Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma
Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma
Active, not recruiting · NCT03478514 · Registry updated 2026-10-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm | Active, not recruiting | Phase 2 | 2026-10-02 | NCT03478514 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Alliance Foundation Trials, LLC. | 12 |
| Pfizer | 431 |
9 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| City of Hope National Medical Center | Duarte | United States | 68 |
| Massachusetts General Hospital | Boston | United States | 1015 |
| Medical University of South Carolina - Hollings Cancer Center | Charleston | United States | 5 |
| Ohio State University | Columbus | United States | 169 |
| Roswell Park Comprehensive Cancer Center | Buffalo | United States | 63 |
| St. Joseph Mercy Hospital Cancer Care Center | Ypsilanti | United States | 1 |
| University of Maryland, Greenebaum Comprehensive Cancer Center | Baltimore | United States | 3 |
| University of North Carolina | Chapel Hill | United States | 101 |
| Weill Cornell Medical College | New York | United States | 58 |